Long term outcomes of Hospital-Identified Clostridium Difficile Infection (HICDI): A retrospective cohort analysis of adult patients in a teaching hospital
Article Sidebar
Main Article Content
Abstract
Objectives: To study long term outcomes of HICDI.
Design, settings and participants: Retrospective cohort study of adult patients diagnosed with HICDI during their admission to a tertiary teaching hospital between January 1st 2012 and December 31st 2016.
Main outcomes: Primary aim was to study two-year mortality outcome and it’s predictors in HICDI patients. Secondary outcomes were to identify characteristics of HICDI and predictors of time to resolution of infection.
Results: A total of 819 adult HICDI episodes were identified. 544 episodes occurring in 466 patients were included in final analysis. Single CDI episodes occurred in 409 patients, 45 patients had 2 episodes and 12 patients had greater than 2 episodes.
Two-year all-cause mortality was 33% (152/409) in single CDI episodes and 61.4% (35/57) for those with greater than one CDI episode. Of the 466 patients, the in-hospital all-cause mortality directly attributed to CDI was 14 patients (3%).
Risk factors predicting long-term mortality were, chemotherapy (AHR(adjusted hazard ratio)2.7; 95% CI 1.90-3.81;p=0.01), low albumin(AHR 2.44; 95% CI 1.83-3.47; p=0.01), ICU admission(AHR 2.09, 95% CI 1.44-3.03; p=0.01) high WBC count (AHR 1.78,CI 1.28-2.30; p=0.01), multiple CDIs (AHR 1.24,95% CI 1.09-1.39; p=0.01) and age (AHR:1.04;95%CI:1.03–1.05;p=0.01).
Most common type of HICDI was Hospital –Acquired CDI (HA-CDI) (55.8 %; n=260). Antibiotic usage before developing CDI significantly delayed the time to resolution of infection (AIRR: 1.35; 95% CI 1.06-1.71; p=0.01). In 1/3rd (n=180) of HICDI episodes, patients were discharged before resolution of diarrhoea. Majority of HICDI episodes (n=371) were treated with metronidazole.
Conclusion: HICDI was associated with significant long term mortality and morbidity. Mortality increased with more than one CDI infection. Antibiotic usage before developing CDI significantly delayed the time to resolution of infection.
Downloads
Article Details
Copyright (c) 2021 Pandhem SR, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing and protecting the author rights is the central aim and core of the publishing business. Peertechz dedicates itself in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. Peertechz licensing terms are formulated to facilitate reuse of the manuscripts published in journals to take maximum advantage of Open Access publication and for the purpose of disseminating knowledge.
We support 'libre' open access, which defines Open Access in true terms as free of charge online access along with usage rights. The usage rights are granted through the use of specific Creative Commons license.
Peertechz accomplice with- [CC BY 4.0]
Explanation
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
With this license, the authors are allowed that after publishing with Peertechz, they can share their research by posting a free draft copy of their article to any repository or website.
'CC BY' license observance:
|
License Name |
Permission to read and download |
Permission to display in a repository |
Permission to translate |
Commercial uses of manuscript |
|
CC BY 4.0 |
Yes |
Yes |
Yes |
Yes |
The authors please note that Creative Commons license is focused on making creative works available for discovery and reuse. Creative Commons licenses provide an alternative to standard copyrights, allowing authors to specify ways that their works can be used without having to grant permission for each individual request. Others who want to reserve all of their rights under copyright law should not use CC licenses.
Kelly CP, LaMont JT (2008) Clostridium difficile--more difficult than ever. N Engl J Med 359: 1932-194040. Link: https://bit.ly/3jHulBS
Bhandari S, Pandey RK, Dahal S, Shahreyar M, Dhakal B, et al. (2018) Risk, Outcomes, and Predictors of Clostridium difficile Infection in Lymphoma: A Nationwide Study. South Med J 111: 628-633. Link: https://bit.ly/375S0XQ
Lessa FC, Winston LG, McDonald LC, Emerging Infections Program C. difficile Surveillance Team (2015) Burden of Clostridium difficile infection in the United States. N Engl J Med 372: 2369-2370. Link: https://bit.ly/3jKqvbo
Gupta A, Khanna S (2014) Community-acquired Clostridium difficile infection: an increasing public health threat. Infect Drug Resist 7: 63-72. Link: https://bit.ly/3di3Bab
Slimings C, Armstrong P, Beckingham WD, Bull AL, Hall L, et al. (2014) Increasing incidence of Clostridium difficile infection, Australia, 2011-2012. Med J Aust 200: 272-276. Link: https://bit.ly/3qiLIeQ
Khanna S, Pardi DS, Aronson L, Kammer PP, Orenstein R, et al. (2012) The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol 107: 89-95. Link: https://bit.ly/3pd3Up0
Viseur N, Lambert M, Delmee M, Van Broeck J, Catry B (2011) Nosocomial and non-nosocomial Clostridium difficile infections in hospitalised patients in Belgium: compulsory surveillance data from 2008 to 2010. Euro surveill 16: 20000. Link: https://bit.ly/377hyDF
Mitchell BG, Gardner A (2012) Mortality and Clostridium difficile infection: a review. Antimicrob Resist Infect Control 1: 20. Link: https://bit.ly/377hFPB
Kenneally C, Rosini JM, Skrupky LP, Doherty JA, Hollands JM, et al. (2007) Analysis of 30-day mortality for clostridium difficile-associated disease in the ICU setting. Chest 132: 418-424. Link: https://bit.ly/3d5NImQ
Kwon JH, Olsen MA, Dubberke ER (2015) The morbidity, mortality, and costs associated with Clostridium difficile infection. Infect Dis Clin North Am 29: 123-134. Link: https://bit.ly/37o0mu3
Kyne L, Hamel MB, Polavaram R, Kelly CP (2002) Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 34: 346-353. Link: https://bit.ly/3qcVRK8
Maroo S, Lamont JT (2006) Recurrent Clostridium Difficile. Gastroenterology 130: 1311-1316. Link: https://bit.ly/3pdiKvu
Wiegand PN, Nathwani D, Wilcox MH, Stephens J, Shelbaya A, et al. (2012) Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. J Hosp Infect 81: 1-14. https://bit.ly/3rLAWy5
Dubberke ER, Butler AM, Reske KA, Agniel D, Olsen MA, et al. (2008) Attributable outcomes of endemic Clostridium difficile-associated disease in nonsurgical patients. Emerg Infect Dis 14: 1031-1038. Link: https://bit.ly/3pm5NzP .
Musher DM, Nuila F, Logan N (2007) The long-term outcome of treatment of Clostridium difficile colitis. Clin Infect Dis 45: 523-524. Link: https://bit.ly/3d4yVc5
Doh YS, Kim YS, Jung HJ, Park YI, Mo JW, et al. (2014) Long-Term Clinical Outcome of Clostridium difficile Infection in Hospitalized Patients: A Single Center Study. Intest Res 12: 299-305. Link: https://bit.ly/2Nhq8Zy
Australian commission on safety and Quality in Health care (2013) Implementation guide for surveillance of clostridium difficile infection. Link: https://bit.ly/3730PkP
Bloomfield MG, Sherwin JC, Gkrania-Klotsas E (2012) Risk factors for mortality in Clostridium difficile infection in the general hospital population: a systematic review. J Hosp Infect 82: 1-12. Link: https://bit.ly/3b1dGFB
Arora V, Kachroo S, Ghantoji SS, Dupont HL, Garey KW (2011) High Horn's index score predicts poor outcomes in patients with Clostridium difficile infection. J Hosp Infect 79: 23-26. Link: https://bit.ly/2MQbU28
Wynell-Mayow W, Cash D, Muniz-Tererra G, Gkrania-Klotsas E, Khanduja V (2017) Factors Affecting Mortality and Length of Stay Following Clostridium Difficile Associated Diarrhoea: Validating A Consistent Scoring System. Arch Clin Microbiol 8: 3. Link: https://bit.ly/2NhqBuM
Eze P, Balsells E, Kyaw MH, Nair H (2017) Risk factors for Clostridium difficile infections - an overview of the evidence base and challenges in data synthesis. J Glob Health 7: 010417. Link: https://bit.ly/2Z9oaNv
Kim JW, Lee KL, Jeong JB, Kim BG, Shin S, et al. (2010) Proton pump inhibitors as a risk factor for recurrence of Clostridium-difficile-associated diarrhea. World J Gastroenterol 16: 3573-3577. Link: https://bit.ly/3aS6rQc
Raines DL, Lopez FA (2011) Clostridium difficile infection in non-HIV-immunocompromised patients and in HIV-infected patients. Curr Gastroenterol Rep 13: 344-350. Link: https://bit.ly/3jGZvcE
Bond SE, Boutlis CS, Yeo WW, Pratt W, Orr ME, et al. (2017) The burden of healthcare-associated Clostridium difficile infection in a non-metropolitan setting. J Hospital Infect 95: 387–393. Link: https://bit.ly/3ad30V1
McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll, KC, et al. (2018) Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 66: e1-e48. Link: https://bit.ly/2Zavg4s
Australian Guidelines for the Prevention and Control of Infection in Healthcare, Canberra (2019) National Health and Medical Research Council. Link: https://bit.ly/3jDTBJm
Reveles KR, Dotson KM, Gonzales-Luna A, Surati D, Endres BT, et al. (2019) Clostridioides (Formerly Clostridium) difficile Infection During Hospitalization Increases the Likelihood of Nonhome Patient Discharge. Clin Infect Dis 68: 1887-1893. Link: https://bit.ly/2LJN979
Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, et al. (2010) Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 31: 431-455. Link: https://bit.ly/2NmFdZH
eTG complete [Internet]. Melbourne (VIC) : Therapeutic Guidelines Ltd. Published April 2019 (eTG December 2019 edition) Clostridium difficle infection.